Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

migraine

This page shows the latest migraine news and features for those working in and with pharma, biotech and healthcare.

Lundbeck drops Parkinson’s drug acquired in €905m deal

Lundbeck drops Parkinson’s drug acquired in €905m deal

It has added to its pipeline under Dunsire with a $1.95bn takeover of Alder Biopharma, adding migraine prevention therapy Vyepti (eptinezumab) – which is launching in competition with rival drugs from

Latest news

More from news
Approximately 26 fully matching, plus 148 partially matching documents found.

Latest Intelligence

  • What Hemingway got right about patient communications What Hemingway got right about patient communications

    as multiple sclerosis and migraine, to monitor their health and track the success of their medication. ... To create Rain Free Days, we worked closely with staff and patients at the National Migraine Centre and Prof Zameel Cader at The John Radcliffe

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Eli Lilly/Dong Pharmaceuticals’ 5-HT1f agonist Reyvow was approved in the US in October 2019 as the first acute treatment for migraine in 20 years. ... Allergan’s Ubrelvy is the only other oral CGRP antagonist approved for acute migraine, which

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    pipeline. He argues, however, that layering in products like Allergan’s blockbuster wrinkle and migraine treatment Botox will improve near-term cashflow and help fund the roll-out of a new ... year. Botox is facing tougher competition in the market

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    Published adherence in migraine-prophylaxis (as a comparable indication) indicates 92.6% adherent at one month, 40.7% at two months, 30.9% at three months, 24.8% at four months,

  • Deal Watch January 2018

    Teva’s CGRP patent portfolio to develop, manufacture and commercialise eptinezumab, its phase III CGRP antibody for the treatment of migraine.  In exchange for the licence, Alder will withdraw its appeal

More from intelligence
Approximately 1 fully matching, plus 26 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 8 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Quick links

Infographics

Multimedia